title: Clinically relevant QTc prolongation is not associated with current dose schedules of LBH589 (panobinostat).
authors.forename: Lei
authors.initials: L
authors.lastname: Zhang
authors.forename: David
authors.initials: D
authors.lastname: Lebwohl
authors.forename: Eric
authors.initials: E
authors.lastname: Masson
authors.forename: Glen
authors.initials: G
authors.lastname: Laird
authors.forename: Michael R
authors.initials: MR
authors.lastname: Cooper
authors.forename: H Miles
authors.initials: HM
authors.lastname: Prince
mesh_terms: D004305:Dose-Response Relationship, Drug; D019337:Hematologic Neoplasms / Q000188:drug therapy; D006801:Humans; D006877:Hydroxamic Acids / Q000008:administration & dosage / Q000009:adverse effects*; D007211:Indoles; D008133:Long QT Syndrome / Q000139:chemically induced*; D000077767:Panobinostat
chemical_list: D006877:Hydroxamic Acids; D007211:Indoles; D000077767:Panobinostat